After vaccination, binding antibody levels:
- peaked at 6 weeks
- dropped weeks 6-25
- rate of decline slowed weeks 25-48
3/ Serum neutralizing antibody titers:
- dropped weeks 6-24
- rate of decline slowed weeks 24-48
- were highest vs D614G (early variant)⚫️>Gamma🟢>Beta🔴>Delta🔵
4/ This same pattern was observed with a pseudovirus assay:
- decline in neutralizing antibody titers over time
- lower neutralizing antibody titers against the Delta variant vs the early D614G variant
5/ See also:
6/ Over time, antibody avidity (i.e. the strength of binding to Spike protein) got better 6-24 weeks after vaccination.
This likely reflects somatic hypermutation & affinity maturation.
7/ They also looked at antibody titers in the lungs (bronchoalveolar lavage, BAL) & nose (nasal washes).
Binding antibody titers in the lungs dropped weeks 6-25, & then the rate of decline slowed.
8/ Among vaccinated primates challenged with Delta virus, antibody titers in the lungs⬆️ & peaked by day 4.
Among unvaccinated primates challenged with Delta virus, antibody titers in the lungs⬆️ days 4-14.
9/ Binding antibody titers in the👃🏾peaked later than in the🫁at 25 weeks & then remained stable out to week 42.
10/
Among vaccinated primates challenged with Delta virus, antibody titers in the👃🏾⬇️by day 4.
Among unvaccinated primates challenged with Delta virus, antibody titers in the👃🏾⬆️ by day 14.
Antibodies in the👃🏾may be cleared differently than in the 🫁.
11/ They also used a Spike protein-ACE2 binding inhibition assay to assess antibody function.
Binding in🫁 peaked at 6 weeks after vaccination & declined by 42 weeks.
12/ The Spike protein-ACE2 binding inhibition assay found that binding in👃🏾increased until week 25 & remained elevated at week 42 after vaccination.
13/ They assessed S protein-specific memory B-cells after vaccination with flow cytometry.
The % of S-protein specific memory B-cell responses peaked at 6 weeks after vaccination & then decreased by week 25.
14/ Over the course of a year, Spike protein-binding B-cells shifted from activated memory phenotype to activated/resting/tissue-like memory cells.
15/ Spike protein-specific T-cell responses were also assessed.
Th1 responses were detected at week 6 & ⬇️by week 25. They were low-undetectable by week 42.
16/ Tfh responses were detectable by week 6 & ⬇️by week 42.
17/ Th2 & CD8+ T-cell responses were low after vaccination.
18/ After Delta virus challenge, there was significantly less viral replication in 🫁 by day 4 among vaccinated vs unvaccinated primates.
19/ After Delta virus challenge, there was significantly less viral replication in👃🏾by day 2 among vaccinated vs unvaccinated primates, but the overall reduction in viral replication was less in👃🏾than in 🫁.
20/ Tissue culture infectious dose was also assessed from 🫁&👃🏾samples.
Viral replication in 🫁&👃🏾 of vaccinated primates was lower than for unvaccinated primates.
By day 4 after Delta virus challenge, replication in🫁was undetectable in almost all vaccinated primates.
21/ Viral replication in the 👃🏾of vaccinated primates was lower than for unvaccinated primates, but not zero.
22/ IN SUMMARY:
Unvaccinated and Moderna vaccinated primates were challenged with the Delta variant ~1 year after vaccination.
Four days after challenge, vaccinated primates had NO culturable virus in the lungs, but virus was culturable in the nose.
23/ Antibody-related protection in the lungs is durable but delayed.
It takes time for memory B-cells to rev up & make antibodies.
24/ Note that enough virus made it into the 🫁 of vaccinated primates to elicit a local anamnestic antibody response and a bump in Spike protein-specific B- & T-cell populations.
25/🫁from vaccinated & unvaccinated primates were examined 7 days after Delta virus challenge.
Viral antigen was detected in🫁of all unvaccinated primates & none of the vaccinated primates.
Inflammation was:
- minimal-moderate among vaccinated
- minimal-severe in unvaccinated
26/ Binding & neutralizing antibody titers declined over one year after vaccination leaving the lungs susceptible to viral infection & replication in the first couple days after challenge.
But the local anamnestic response was sufficient to prevent severe disease.
27/ Neutralizing antibodies are a good correlate of protection soon after vaccination.
A year after vaccination, memory B-cells may be a better correlate of protection.
28/ If the goal is to prevent infection in the👃🏾&🫁, it’s likely primates (& people) will need repeated (yearly?) vaccine boosters.
If the goal is to prevent severe disease, protection from the mRNA vaccines appears durable (at least out to 48 weeks).
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/ There's good evidence that to protect against severe disease, hospitalization, & death, the following would benefit from an additional dose of COVID vaccine:
- immunocompromised persons
- people 60-65+ (? 40+)
- residents of long-term care facilities
3/ What should our goal be with the vaccines?
- Prevention of severe disease, hospitalization, & death
- Prevention of symptomatic infection (which means trying to prevent ALL infections since we can't always predict who'll be symptomatic)